Published in J Invest Dermatol on October 08, 2009
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 3.10
Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol (2017) 0.75
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell (1993) 10.36
Skin cancers after organ transplantation. N Engl J Med (2003) 6.65
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet (1999) 5.29
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development (2000) 4.33
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol (2005) 4.03
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene (2007) 2.83
Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet (1995) 2.51
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene (2000) 2.27
Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Am J Hum Genet (2002) 1.88
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer (2004) 1.88
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet (2005) 1.74
Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology (2001) 1.72
Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res (2006) 1.46
Familial acanthosis nigricans due to K650T FGFR3 mutation. Arch Dermatol (2007) 1.33
Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling. FASEB J (2000) 1.26
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer (2007) 1.23
Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res (2005) 1.11
No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene (2001) 0.96
Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene (2000) 0.95
Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer (2009) 0.95
Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines. Head Neck (1989) 0.93
Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. J Surg Oncol (2007) 0.90
Epidermal growth factor receptors in different skin tumors. Dermatologica (1985) 0.80
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst (2003) 3.65
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res (2009) 2.27
Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol (2006) 2.04
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res (2008) 1.98
Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev (2007) 1.98
Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol (2009) 1.87
Ambiguous melanocytic tumors with loss of 3p21. Am J Surg Pathol (2014) 1.83
The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res (2011) 1.81
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78
MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol (2008) 1.72
A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Hum Mol Genet (2002) 1.69
A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol (2012) 1.57
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res (2011) 1.47
Metastatic melanoma in association with a giant congenital melanocytic nevus in an adult: controversial CGH findings. Am J Dermatopathol (2015) 1.45
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
The presence of polyomavirus in non-melanoma skin cancer in organ transplant recipients is rare. J Invest Dermatol (2008) 1.43
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A (2002) 1.30
Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res (2012) 1.23
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res (2013) 1.20
PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol (2006) 1.19
Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther (2006) 1.16
Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res (2009) 1.14
Germline variation controls the architecture of somatic alterations in tumors. PLoS Genet (2010) 1.11
Molecular analysis of a case of nevus of ota showing progressive evolution to melanoma with intermediate stages resembling cellular blue nevus. Am J Dermatopathol (2010) 1.08
Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. J Natl Cancer Inst (2013) 1.06
Loss of the p53/p63 regulated desmosomal protein Perp promotes tumorigenesis. PLoS Genet (2010) 1.04
Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J Invest Dermatol (2008) 1.03
GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathol (2012) 1.00
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
KIT as a therapeutic target in melanoma. J Invest Dermatol (2010) 0.97
Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am J Pathol (2004) 0.97
Persistent (recurrent) Spitz nevi: a histopathologic, immunohistochemical, and molecular pathologic study of 22 cases. Am J Surg Pathol (2002) 0.93
Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma. Am J Surg Pathol (2010) 0.92
SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis. Cancer Res (2013) 0.90
Signalling of the M3-muscarinic receptor to the anti-apoptotic pathway. Biochem J (2004) 0.90
Fluorescence in situ hybridization as an ancillary tool in the diagnosis of ambiguous melanocytic neoplasms: a review of 804 cases. Am J Surg Pathol (2014) 0.90
An unconventional deep penetrating melanocytic nevus with microscopic involvement of regional lymph nodes. J Cutan Pathol (2012) 0.89
Molecular-microscopical correlation in dermatopathology. J Cutan Pathol (2011) 0.87
The DNA damage-binding protein XPC is a frequent target for inactivation in squamous cell carcinomas. Am J Pathol (2010) 0.87
Atypical junctional melanocytic proliferations in benign lichenoid keratosis. Hum Pathol (2003) 0.86
An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second 'primary' tumor. J Cutan Pathol (2011) 0.85
Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. Am J Surg Pathol (2015) 0.85
Genome-wide associations studies for melanoma and nevi. Pigment Cell Melanoma Res (2009) 0.84
Absence of PDGFRA mutations in primary melanoma. J Invest Dermatol (2007) 0.83
Genomic analysis of blue nevi and related dermal melanocytic proliferations. Am J Surg Pathol (2005) 0.83
MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A (2013) 0.81
Consumption of the epidermis: a diagnostic criterion for the differential diagnosis of melanoma and Spitz nevus. Am J Surg Pathol (2004) 0.81
In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival. Pigment Cell Melanoma Res (2014) 0.81
Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res (2009) 0.81
Beyond BRAF in melanoma. Curr Top Microbiol Immunol (2012) 0.81
Coalescing, nevoid papules in an infant. Arch Dermatol (2005) 0.80
Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma. Int J Cancer (2013) 0.79
Assessment of copy number status of chromosomes 6 and 11 by FISH provides independent prognostic information in primary melanoma. Am J Surg Pathol (2011) 0.79
Establishment of a novel melanoma cell line SMYM-PRGP showing cytogenetic and biological characteristics of the radial growth phase of acral melanomas. Cancer Sci (2007) 0.77
Chromosomal copy number analysis in melanoma diagnostics. Methods Mol Biol (2014) 0.77
Hypothesis: a role for telomere crisis in spontaneous regression of melanoma. Arch Dermatol (2003) 0.77
Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma. Am J Surg Pathol (2011) 0.77
Expanding the genetic spectrum of pigmentation. Pigment Cell Melanoma Res (2007) 0.76
Comment on "Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT". J Invest Dermatol (2010) 0.75
Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer. Exp Dermatol (2009) 0.75
The Genetic Evolution of Melanoma. N Engl J Med (2016) 0.75
Lack of somatic alterations of MC1R in primary melanoma. Pigment Cell Melanoma Res (2007) 0.75
Neuroanatomy: From fin to forelimb. Nature (2010) 0.75
Absence of somatic mutations of NEMO in keratoacanthoma. J Invest Dermatol (2009) 0.75
Filling the gaps in the genomic catalogue of melanoma subtypes. Pigment Cell Melanoma Res (2017) 0.75
Two cases of unusual acral melanocytic tumors: illustration of molecular cytogenetics as a diagnostic tool. Hum Pathol (2003) 0.75